Psilocybin formulation Modulates Anxiety-Like Behaviour in Rat Autism Model VANCOUVER, BC, March 29, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders, is pleased to announce, it has found early indications…

Source

Previous articleHorizons ETFs Completes Rebalance of World’s First Psychedelics ETF
Next articleMindMed Announces the Addition of Stanford University Neuroscientist as Chair of the Scientific Advisory Board